Connect your AI

ADMA Biologics ADMA Accrued interest

Accrued interest at other companies

Aurinia PharmaceuticalsAUPH

$700K+250%

Charles River LaboratoriesCRL

——

Other financials

Income statement

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:InterestPayableCurrent.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's accrued interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ADMA Biologics's accrued interest?: ADMA Biologics (ADMA) reported accrued interest of $750K in Q1 2026.
How has ADMA Biologics's accrued interest changed year-over-year?: ADMA Biologics's accrued interest decreased by 60.4% year-over-year, from $1.89M to $750K.
What is the long-term trend for ADMA Biologics's accrued interest?: Over 2 years (2023 to 2025), ADMA Biologics's accrued interest has grown at a -43.9% compound annual growth rate (CAGR), from $546K to $172K.
What does accrued interest mean?: Interest expense accrued but not yet paid on outstanding debt obligations, based on contractual interest rates and time elapsed.